Drug Profile

Adavosertib - AstraZeneca

Alternative Names: AZD-1775; L001739996-008U; MK-1775; MK-1775 hemihydrate

Latest Information Update: 09 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Merck & Co
Developer AstraZeneca; Canadian Cancer Trials Group; Cancer Research UK; Dana-Farber Cancer Institute; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Texas M. D. Anderson Cancer Center; University of Washington
Class Aniline compounds; Antineoplastics; Piperazines; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
Mechanism of Action WEE1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer
New Molecular Entity Yes

Discontinued Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Haematological disorders; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Uterine cancer; Vulvovaginal cancer

25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2024)
25 Apr 2025 Pharmacodynamics data from preclinical trial in Ovarian cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
30 Jan 2025 MD Anderson Cancer Center, in collaboration with National Cancer Institute completes enrolment in its phase-II clinical trials in Ovarian cancer (Recurrent, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03579316)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com